Influenza vaccine effectiveness against A(H3N2) during the delayed 2021/22 epidemic in Canada

Influenza virus circulation virtually ceased in Canada during the COVID-19 pandemic, re-emerging with the relaxation of restrictions in spring 2022. Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network reports 2021/22 vaccine effectiveness of 36% (95% CI: −38 to 71)...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Shinhye, Chuang, Erica SY, Sabaiduc, Suzana, Olsha, Romy, Kaweski, Samantha E, Zelyas, Nathan, Gubbay, Jonathan B, Jassem, Agatha N, Charest, Hugues, De Serres, Gaston, Dickinson, James A, Skowronski, Danuta M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2022
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511683/
https://www.ncbi.nlm.nih.gov/pubmed/36148674
http://dx.doi.org/10.2807/1560-7917.ES.2022.27.38.2200720
Descripción
Sumario:Influenza virus circulation virtually ceased in Canada during the COVID-19 pandemic, re-emerging with the relaxation of restrictions in spring 2022. Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network reports 2021/22 vaccine effectiveness of 36% (95% CI: −38 to 71) against late-season illness due to influenza A(H3N2) clade 3C.2a1b.2a.2 viruses, considered antigenically distinct from the 3C.2a1b.2a.1 vaccine strain. Findings reinforce the World Health Organization’s decision to update the 2022/23 northern hemisphere vaccine to a more representative A(H3N2) clade 3C.2a1b.2a.2 strain.

Ejemplares similares